Home

Testimonial - Catherine Berjal and Anne-Sophie d’Andlau

Co-founders of the CIAM (Charity Investment Asset Management) hedge fund

Catherine Berjal and Anne-Sophie d'Andlau, who have been involved with the Gustave Roussy Foundation since 2016, have chosen to support research on pediatric cancers. Their commitment is driven by their convictions and their desire to contribute to research advances that benefit sick children.

Catherine Berjal - Anne-Sophie d’Andlau

Why Support Gustave Roussy?

In 2016, a meeting with Frédéric Lemos (president of LFPI Reim and chair of the campaign committee “Curing Childhood Cancer in the 21st Century” at the Gustave Roussy Foundation) and their discovery of his commitment to pediatric cancer research marked the beginning of their involvement with the Gustave Roussy Foundation.

As mothers, Catherine Berjal and Anne-Sophie d’Andlau feel particularly drawn to the fight against childhood cancers and wish to contribute, in their own way, to advances in research.

Verbatim

"We are convinced that we shouldn't wait until we are faced with illness to take action and give."

What is philanthropy?

Philanthropy refers to the voluntary commitment of individuals or companies to initiatives that serve the public good, particularly in the areas of health, research, education, and social solidarity.

The Impact of Donations on Research

Support for the pediatric oncology campaign has helped launch research projects and recruit top-tier scientific teams.

Each year, the advances presented by researchers allow donors to see tangible results from their commitment to helping children with 

Key Figures

  • 2016

    the start of their involvement with the Gustave Roussy Foundation.

  • 10 million euros

    additional funding target set to further the development of pediatric oncology research

Engaging the Business Community

Catherine Berjal and Anne-Sophie d'Andlau are encouraging more companies—particularly those in the financial sector—to support organizations and foundations dedicated to fighting the disease.

For them, collective action is a key driver for accelerating progress in research.

Pour approfondir